COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial
20 July 2020 14:40 BST Interim data showed strong antibody and T-cell responses Interim results from the ongoing Phase I/II ...
Read moreDetails20 July 2020 14:40 BST Interim data showed strong antibody and T-cell responses Interim results from the ongoing Phase I/II ...
Read moreDetails30 April 2020 Collaboration will enable global development, manufacturing and distribution of the vaccine AstraZeneca and the University of Oxford ...
Read moreDetails© 2018 | Fortune World Media | MEDIA & ENTERTAINMENT CO. IN | Powered by Raja's Digital
© 2018 | Fortune World Media | MEDIA & ENTERTAINMENT CO. IN | Powered by Raja's Digital